Secondary hyperparathyroidism

This trial investigates how the drug zoledronic acid is processed in the body of people with chronic kidney disease who are on dialysis and also have osteoporosis. It aims to find the best dose—either 2.5 mg or 5 mg—given as a single intravenous injection during a dialysis sessio…

This study tests whether a newer type of dialysis filter (medium cut-off membrane) can better manage bone and mineral problems common in people with end-stage kidney disease. Thirty adults on maintenance dialysis will try both the new and standard filters for three months each. R…

This study tests whether a low dose of colchicine, a common anti-inflammatory drug, can slow down blood vessel hardening and bone problems in people with stage 3 chronic kidney disease. About 60 adults will take colchicine or receive usual care for 12 months. The goal is to see i…

This study compares two vitamin D medications—doxercalciferol (given through a vein) and calcitriol (taken by mouth)—to see which is better at lowering parathyroid hormone levels in kidney dialysis patients. About 98 adults on dialysis with high parathyroid hormone will take part…

This study tests an extended-release vitamin D capsule (CTAP101) in 40 children aged 8 to 17 with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism, and low vitamin D. Participants take one capsule daily at bedtime for 8 weeks. The goal is to see how the body pro…

This study will follow 1000 adults with advanced chronic kidney disease (stage 4-5) to learn why they face higher risks of bone fractures and heart disease. Researchers will track bone turnover markers, calcium and phosphate levels, and kidney function over time. No new treatment…

This study will examine how quality of life changes after parathyroid surgery in 60 adults with kidney failure and secondary hyperparathyroidism. Researchers will use a database to compare quality-of-life scores, anxiety, and depression before and after surgery. The goal is to be…